A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Sandro PignataGiovanni ScambiaAlessandro VillanucciEmanuele NaglieriMikel Arruti IbarbiaFederica BrusaHugues BourgeoisRoberto SorioAntonio CasadoDietmar ReichertCatherine DopchieBeatriz De RivasLuis Miguel de SandePublished in: The oncologist (2021)
This noninterventional, prospective study, conducted in 57 reference sites across Europe, consistently confirmed that trabectedin plus pegylated liposomal doxorubicin (PLD) in routine clinical practice represents a clinically meaningful and safe option for women with platinum-sensitive recurrent ovarian cancer. Although the study population represented a heterogeneous, older, and more pretreated population than those in prospective clinical trials, the combination of trabectedin plus PLD induced comparable clinical benefits, with a similar and manageable safety profile. Overall, these findings show that trabectedin in combination with PLD maintains antitumor activity when administered to heavily pretreated patients in real-life clinical practice.